T-cell Therapy Market Size Worth $32.75 Billion By 2030

T-cell Therapy Market Growth & Trends

The global T-cell therapy market size is expected to reach USD 32.75 billion by 2030 and is expected to register a CAGR of 35.33% from 2023 to 2030 according to a new report by Grand View Research, Inc. The landmark approval of Kymriah and Yescarta has boosted advancements in the market. The launch of such therapies has strengthened cash flow for innovation in this area resulting in market growth.

The shifting patients’ preference from first-line stem cell transplant and chemotherapy towards chimeric antigen receptor (CAR) T cell therapy is expected to create growth opportunities for the market growth. On the other hand, the number of diseases that T-cell therapies are being tested on is constantly growing. With increasing investments in other areas, oncological illnesses are the focus of significant interest.

Rise in the prevalence of multiple myeloma and the rise in incidences of leukemia and lymphomia resulted in high adoption of CAR-T cell therapy, which boosts market growth. According to the Leukemia & Lymphoma Society (LLS), estimated around 54,000 children and adolescents above 20 years in the U.S. have lymphoma, leukaemia, myeloma,and myelodysplastic syndromes (MDS). Moreover, the same source stated that around 1,898,160 new cancer cases will be diagnosed in the U.S. in 2021, with new instances of leukaemia, lymphoma, and myeloma likely to represent 9.8% of those cases.

An increase in clinical trial activity along with new therapy launches is expected to boost the market growth in the coming years. For instance, in December 2021, Novartis declared to launch T-ChargeTM, its next-generation CAR-T platform, which will be the basis for a number of novel investigational CAR-T cell therapies in the company's pipeline. The first Novartis CAR-T cell treatments created with this platform, YTB323 (anti-CD19) and PHE885 (anti-BCMA), were presented by Novartis at the 63rd American Society of Hematology Annual Meeting & Exposition (ASH) 2021.

The development of CAR T treatments for non-hematological malignancies has been significantly hampered by antigen concerns and associated toxicity issues. To overcome the difficulty and increase the use of T-cell treatment in indication types such as brain cancer and melanoma, key players are utilizing a data-driven approach to research this area.

 Request a free sample copy or view report summary: T-cell Therapy Market Report

T-cell Therapy Market Report Highlights

• By Modality, the research-based market for T-cell therapies is expected to occupy the larger share of market space due to high number of T-cell therapy products under clinical trials.

• Commercialized T-cell therapies are expected to show significant market share in the coming years owing to the increase in the number of product approval from the regulatory body.

• By therapy type, CAR-T cell therapy dominated the segment in 2022 owing to the increase in clinical trials for CAR-T therapy products. Moreover, an increase in the usage of these therapies in different cancer is expected to boost segment growth.

• Haematological malignancies dominated the indication segment in 2022. In order to treat lymphoma and acute lymphocytic leukaemia (ALL), the most common target of CAR T-cell therapies is CD19 on B-cells, which has led to the approval of five different CAR T therapies.

• North America dominated the overall global market. The regional growth is attributed to the increasing clinical trials, strong research, and increasing regulatory approval, resulting increase in the uptake of these therapies.

T-cell Therapy Market Segmentation

Grand View Research has segmented the global T-cell therapy market based on modality, therapy type, indication, and region:

T-cell Therapy Type Outlook (Revenue, USD Million, 2018 - 2030)

• CAR T-cell Therapy

• T Cell Receptor (TCR)-based

• Tumor Infiltrating Lymphocytes (TIL)-based

T-cell Therapy Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Hematologic Malignancies

  • Lymphoma

  • Leukemia

  • Myeloma

• Solid Tumors

  • Melanoma

  • Brain & Central Nervous System

  • Liver Cancer

  • Others

• Others

T-cell Therapy Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

• Asia Pacific

  • Japan

  • China

• Rest of the World

List of Key Players of T-cell Therapy Market

• Novartis AG

• Merck KGaA

• Gilead Sciences Inc.

• TCR2 Therapeutics Inc

• Bluebird Bio Inc.

• Sorrento Therapeutics

• Fate Therapeutics

• Pfizer Inc.

• Amgen

• Celgene Corporation